Oncology Related Products
Detailed molecular biology
and cellular studies on radio-modifying action of the molecule were instrumental
in realising its therapeutic potential for enhancing the effect of radiotherapy
and making it effective in cancers having poor response to radiotherapy.
Examples of such cancers include brain tumour and sarcomas. As this is a
frequent clinical problem, the effect of 2-DG on non-surgical treatment of
cancers is increasingly being realised and is expected to be very significant.
The technology has been transferred to Dr Reddy’s Laboratory after regulatory
approvals and successful completion of the initial clinical trials to fulfill
the Societal Mission of DRDO.
ANT POST ANT POST
1h 99mTc-CDTMP scan 3h 99mTc-MDP scan 1h 99mTc-CDTMP scan.
A number of new
radio-pharmaceuticals have been developed specifically for targeting cancerous
lesions. The new radiopharmaceuticals have the twin potential for imaging or
therapy of the cancerous lesions using conventional nuclear medicine
radionuclides. The radiopharmaceuticals targeting primary lesions are usually
based on antibodies for receptors, while those targeting bone secondary are
phosphonate derivatives with affinity towards abnormal bone. Some of the
antibody-based radiopharmaceuticals developed by DRDO are anti-EGFR antibody
chelated to DOTA-Ph-Al derivative that acts as a bi-functional chelate, and
radiopharmaceutical Tc-99m CDTMP for targeting the abnormal bone.